Catalog No. |
TD-HY257026 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG1-nd |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20 |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P11836 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
2H7,PR-070769/PR070769/R-1594/RG-1594,CAS:637334-45-3 |
Background |
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC). |
Note |
For research use only. Not for use in clinical or therapeutic applications. |